Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
MYLAN Dec-18 |
AUROBINDO PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 3,495 | - | |
Low | Rs | 527 | 1,924 | - | |
Sales per share (Unadj.) | Rs | 333.9 | 1,608.1 | - | |
Earnings per share (Unadj.) | Rs | 40.4 | 43.7 | - | |
Cash flow per share (Unadj.) | Rs | 51.8 | 344.8 | - | |
Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
Dividend yield (eoy) | % | 0.4 | 0 | - | |
Book value per share (Unadj.) | Rs | 237.1 | 1,739.7 | - | |
Shares outstanding (eoy) | m | 585.91 | 514.50 | - | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 1.7 | 120.6% | |
Avg P/E ratio | x | 16.8 | 62.0 | 27.1% | |
P/CF ratio (eoy) | x | 13.1 | 7.9 | 166.8% | |
Price / Book Value ratio | x | 2.9 | 1.6 | 183.8% | |
Dividend payout | % | 6.2 | 0 | - | |
Avg Mkt Cap | Rs m | 397,569 | 1,393,882 | 28.5% | |
No. of employees | `000 | 17.9 | 35.0 | 51.0% | |
Total wages/salary | Rs m | 25,849 | 0 | - | |
Avg. sales/employee | Rs Th | 10,956.9 | 23,639.1 | 46.4% | |
Avg. wages/employee | Rs Th | 1,447.7 | 0 | - | |
Avg. net profit/employee | Rs Th | 1,324.3 | 641.9 | 206.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 827,370 | 23.6% | |
Other income | Rs m | 1,553 | 0 | - | |
Total revenues | Rs m | 197,189 | 827,370 | 23.8% | |
Gross profit | Rs m | 39,519 | 214,093 | 18.5% | |
Depreciation | Rs m | 6,680 | 154,916 | 4.3% | |
Interest | Rs m | 2,626 | 39,794 | 6.6% | |
Profit before tax | Rs m | 31,767 | 19,383 | 163.9% | |
Minority Interest | Rs m | 27 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
Tax | Rs m | 7,269 | -3,084 | -235.7% | |
Profit after tax | Rs m | 23,645 | 22,467 | 105.2% | |
Gross profit margin | % | 20.2 | 25.9 | 78.1% | |
Effective tax rate | % | 22.9 | -15.9 | -143.8% | |
Net profit margin | % | 12.1 | 2.7 | 445.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 462,003 | 33.3% | |
Current liabilities | Rs m | 120,429 | 336,851 | 35.8% | |
Net working cap to sales | % | 17.0 | 15.1 | 112.2% | |
Current ratio | x | 1.3 | 1.4 | 93.0% | |
Inventory Days | Days | 135 | 84 | 161.8% | |
Debtors Days | Days | 64 | 93 | 68.3% | |
Net fixed assets | Rs m | 103,909 | 160,496 | 64.7% | |
Share capital | Rs m | 586 | 441 | 133.0% | |
Net worth | Rs m | 138,908 | 895,063 | 15.5% | |
Long term debt | Rs m | 1,800 | 966,060 | 0.2% | |
Total assets | Rs m | 264,544 | 2,400,907 | 11.0% | |
Interest coverage | x | 13.1 | 1.5 | 880.7% | |
Debt to equity ratio | x | 0 | 1.1 | 1.2% | |
Sales to assets ratio | x | 0.7 | 0.3 | 214.6% | |
Return on assets | % | 9.9 | 2.6 | 383.0% | |
Return on equity | % | 17.0 | 2.5 | 678.2% | |
Return on capital | % | 23.8 | 3.2 | 749.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | 171,928 | 9.4% | |
From Investments | Rs m | -28,768 | -88,868 | 32.4% | |
From Financial Activity | Rs m | 19,191 | -80,094 | -24.0% | |
Net Cashflow | Rs m | 6,656 | 1,424 | 467.3% |
Compare AUROBINDO PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare AUROBINDO PHARMA With: STRIDES PHARMA SCIENCE LUPIN FULFORD INDIA NOVARTIS SUVEN LIFE SCIENCES
Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More